Live Updates > Live Update Details
2025-09-12 15:39:05
[Shanghai Pharmaceuticals' Antipsychotic Drug Receives Marketing Authorization in the Philippines] ⑴ Shanghai Pharmaceuticals announced that its subsidiary, Shanghai SPH Sino-Western Pharmaceutical Co., Ltd., has obtained a drug registration certificate from the Philippine Food and Drug Administration (FDA). ⑵ The drug has been officially approved for marketing in the Philippine market, with registration fees of approximately 50,000 yuan. ⑶ Aripiprazole tablets are an antipsychotic medication primarily used to treat manic episodes of schizophrenia and bipolar disorder. ⑷ The drug can also be used as an adjunctive treatment for depression. ⑸ In 2024, total sales of aripiprazole tablets (10mg) in the Philippine market reached US$2.39 million.
